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Abstract
In Africa, herbal medicines are often used as primary treatment for HIV/AIDS and for HIV-related
problems. In general, traditional medicines are not well researched, and are poorly regulated. We
review the evidence and safety concerns related to the use of two specific African herbals, which
are currently recommended by the Ministry of Health in South Africa and member states for use
in HIV: African Potato and Sutherlandia. We review the pharmacology, toxicology and
pharmacokinetics of these herbal medicines. Despite the popularity of their use and the support of
Ministries of Health and NGOs in some African countries, no clinical trials of efficacy exist, and
low-level evidence of harm identifies the potential for drug interactions with antiretroviral drugs.
Efforts should be made by mainstream health professionals to provide validated information to
traditional healers and patients on the judicious use of herbal remedies. This may reduce harm
through failed expectations, pharmacologic adverse events including possible drug/herb
interactions and unnecessary added therapeutic costs. Efforts should also be directed at evaluating
the possible benefits of natural products in HIV/AIDS treatment.
The use of traditional medicine and Natural Health Prod-
ucts is widespread among those living with HIV infection
[1]. Many patients take a broad range of natural health
products (NHPs) in addition to their conventional thera-
peutic products [2-4]. In Africa, traditional herbal medi-
cines are often used as primary treatment for HIV/AIDS
and for HIV-related problems including dermatological
disorders, nausea, depression, insomnia, and weak-
ness[2,5-8]. Some herbal and traditional medicines are
not well-researched, poorly regulated, may contain adul-
terated products, and may produce adverse effects [8-13].
Notwithstanding these concerns, the use of traditional
medicines by Africans living with HIV is believed to be
widespread, although insufficiently documented [14-16].
Despite a paucity of evidence on effectiveness, and the
possibility of harm, the Ministries of Health of several
African nations currently promote traditional medicines
for the treatment of HIV and associated symptoms
[12,17]. In the case of South Africa, the Ministry of Health
is actively promoting the use of traditional medicines with
antiretroviral treatments[18].
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AIDS treatment in sub-Saharan Africa include Hypoxis
hemerocallidea (common name: African potato), and Suth-
erlandia. These two herbal remedies are currently recom-
mended by the South African Ministry of Health for HIV
management [17]. The 14 member states of the South
African Development Community (SADC) which
includes Angola, Botswana, Democratic Republic of
Congo, Lesotho, Malawi, Mauritius, Mozambique,
Namibia, Seychelles, South Africa, Swaziland, Tanzania,
Zambia, and Zimbabwe, also support their use [19].
Responding to the compelling need for evidence regard-
ing traditional medicines, we reviewed the current evi-
dence for the use of these herbal remedies in HIV care.
Methods
With the aid of an information specialist, we searched the
following databases independently, in duplicate (from
inception to December 2004):AltHealthWatch, AMED,
CancerLit, CinAhl, Cochrane Controlled Trials Register
(CENTRAL), MedLine, and EMBASE. In order to identify
unpublished research, we searched Clinical trials.gov,
National Research Register (UK) and the Meta-Register.
Searches were not limited by language. We additionally
searched bibliographies of identified reviews and con-
tacted experts in the field. The following search terms were
used, but not limited to: "Medicine, African Traditional",
"Hypox*", "Sutherlandia", and "HIV."
Hypoxis hemerocallidea
Common names
Magic muthi, yellow stars, star lily, African potato (Eng.);
sterretjie, Afrika-patat (Afr.); inkomfe, ilabatheka, sterb-
lom, gifbol, lotsane, molikharatsa[20,21]
Hypoxis is a well-known genus of the family Hypoxi-
daceae. Easily recognizable by its bright yellow star-
shaped flowers and strap-like leaves, it has a long history
of medicinal use on the African continent. The South Afri-
can primary health care community is currently using
hypoxis as an immunostimulant for patients with HIV/
AIDS. A daily dose of 2,400 mg of raw plant is purported
to be therapeutically effective [22]. Within the genus, two
species, H. hemerocallidea and H. colchicifolia are particu-
larly popular both as African traditional remedies and for
the preparation of herbal teas and tinctures.
Rootstocks of this plant have been used by Zulu tradi-
tional healers for centuries in the treatment of urinary
infections, heart weakness, internal tumors, and nervous
disorders [21]. Other unproven uses for this herb include
benign prostatic hypertrophy, cancer and hyperglycemia
[23-25]. The corms of H. hemerocallidea are being used for
immune related illnesses such as the common cold, flu,
arthritis, cancer and HIV/AIDS. There is some indirect evi-
dence that sterols and sterolins, which are found in the
root of Hypoxis, have the potential to enhance immunity
[26-28]. The popular press in South Africa is promoting
preparations of Hypoxis as an agent that can boost immu-
nity in HIV/AIDS patients [29,30]. Multiple websites,
popular magazines, and even the South African Ministry
of Health have supported this assertion [29-32]. Irrespec-
tive of the evidence, many Africans claim benefit from eat-
ing the root of H. hemerocallidea [7,14].
Chemical constituents
An important constituent of the plant is a nor-lignan gly-
coside called hypoxoside, which once in the human gut,
readily converts to the aglycone, rooperol, a biologically
active compound that is purported to have medicinal
properties [22,33]. The plant also contains various sterols
(β-sitosterol, stigmasterol) and their glycosides (sterolins)
such as β-sitosterol glycoside and stanols such as sitosta-
nol also called stigmastanol, which have also been pur-
ported to have important biological activity [26,28].
Pharmacology and Pharmacokinetics
Hypoxoside
Hypoxoside is not absorbed intact into the blood stream.
Once in the body, hypoxoside is converted into its agly-
cone, rooperol, a potent antioxidant [34]. This conversion
is mediated by beta-glucosidase, an enzyme found pre-
dominantly in the gastrointestinal tract. This particular
enzyme is released by rapidly dividing cancer cells.
Phase I biotransformation of both Hypoxoside and rooperol
likely occurs via the P450 system and most likely by CYP
3A4 [35]. A multi-dosage trial found only diglucuronide,
disulphate, and mixed glucuronide-sulphate metabolites
of these two principal constituents in the serum of recipi-
ents. Elimination of the metabolites follows first order
kinetics with half lives ranging from 20 hours for the two
minor metabolites (i.e., diglucuronide and disulphate), to
50 hours for the major metabolite (i.e., the mixed glu-
curonide-sulphate)[22].
Our group recently reported Hypoxis' effect on the P-450
system CYP 3A4 enzyme, the drug transporter P-glycopro-
tein (P-gp), and the pregnane X receptor (PXR) [35].
Hypoxis inhibited up to 86% of the normal CYP 3A4 iso-
form activity. P-glycoprotein showed moderate activity
from exposure to Hypoxis, showing 42–51% of the activity
strength relative to the known P-gp inhibitor verapamil.
Exposure to Hypoxis resulted in an almost 2-fold activa-
tion of the PXR (p < 0.05). This activation was dose-
dependent. Whilst the concentrations used in the in vitro
experiments were relatively high, the study nevertheless
demonstrated that Hypoxis possesses the potential to inter-
act with HIV drug metabolizing enzymes, which could
subsequently lead to drug resistance, drug toxicity and/orPage 2 of 6
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evidence is only from one in vitro model and may not
translate to the same effect in vivo.
Toxicity
A Phase I trial in cancer patients failed to establish any
clinical, hematological, or biochemical toxicities that
could be ascribed to the ingestion of hypoxoside [24].
One recipient did experience an episode of anxiety, nau-
sea, vomiting and diarrhea which was possibly hypoxo-
side related. The data and safety monitoring committee
recently terminated a clinical trial of therapeutic effective-
ness in HIV/AIDS patients citing apparent bone marrow
suppression [36]. Supporters of this herbal medicine have
disputed these inferences [37].
Hypoxoside, when infused in anaesthetized chacma
baboons, had no effect on the cardiovascular system,
whereas rooperol exerted moderate stimulation during
drug administration. The cardiac output increased
together with systemic and pulmonary arterial pressures
and these changes were not accompanied by changes in
heart rate, vascular resistances or in the filling pressures of
the heart. These findings are suggestive of increased myo-
cardial contractility, possibly related to rooperol's cate-
chol structure. It is likely that these cardio stimulatory
effects will prove to be clinically benign [22]. The molec-
ular basis of rooperol toxicity still needs to be clarified.
Biochemical studies have shown that rooperol is a potent
inhibitor of leukotriene synthesis in polymorphonuclear
leucocytes at a concentration of 1 µM or less [22].
Sutherlandia Frutescens subspecies Microphylla
Common names
Insiswa, Unwele, Mukakana, Phetola, Lerumo-lamadi,
cancer bush, kankerbos, kankerbossie [38,39]
Background
The flowering shrub S. frutescens is a member of the Faba-
cea family. The recommended therapeutic dose of Suther-
landia in humans is 9 mg/kg/day[40]. Sutherlandia has
been used in the treatment of cancer, tuberculosis, diabe-
tes, chronic fatigue syndrome, influenza, rheumatoid
arthritis, osteoarthritis, peptic ulcers, gastritis, reflux
esophagitis, menopausal symptoms, anxiety, clinical
depression and HIV infection [38,39]. The South African
Ministry of Health has concluded that this product is safe
based on primate safety studies.
However, scientific data relating to the mechanism
whereby Sutherlandia acts on the immune system has not
been comprehensively documented. Fernandes et al [41]
recently described the antioxidant potential of Sutherlan-
dia frutescens where extracts from hot water possessed
superoxide as well as hydrogen peroxide scavenging activ-
ities which could account for anti-inflammatory proper-
ties. In a study by Tai et al, [42] ethanolic extracts were
shown to have an anti-proliferative effect on several
human tumor cell lines but did not show significant anti-
oxidant activity.
Phyto Nova, of South Africa, is the principal distributor of
both the powdered and encapsulated forms of this herb,
and has attempted to evaluate the purported benefits of
this remedy in HIV/AIDS treatment[38]. A definitive con-
clusion has not yet been reached. Despite the paucity of
data, the South African Ministry of Health and member
states currently recommend the use of this herbal remedy
for HIV/AIDS treatment[17,40].
Constituents
The principal constituents of S. frutescens purported to be
active include L-canavanine, GABA, and D-pinitol. L-
canavanine is a non-protein amino acid that is the L-2-
amino-4-guanidinooxy structural analogue of L-arginine.
There is about 30–40 mg of L-canavanine per dry gram of
the S. frutescens leaf[38]. D-pinitol is a type of sugar found
in many types of legumes and is classified as a chiro-inosi-
tol. It is also known as 3-O-methyl-D-chiro-inositol, or 3-
0-methyl-1,2,4 cis-3,5,6 trans-hexahydroxy-cyclohexanol.
GABA (gabba-amino butyric acid) is both an amino acid
and inhibitory neurotransmitter. It is found at levels of 14
mg per gram dry leaf of S. frutescens[38].
One of the chemical constituents of Sutherlandia, L-cana-
vanine, is an arginine analogue. L-canavanine has been
reported to have anti-viral activity against influenza and
retroviruses, including HIV [43]. A US patent registered in
1988 claimed that 95% of HIV-infected lymphocytes were
selectively destroyed in vitro. Unfortunately, no further
studies of the effect of this herb on HIV have confirmed
this claim. D-pinitol another important constituent of
Sutherlandia has also been suggested for the treatment of
wasting in cancer and AIDS patients although evidence is
scant[44].
Pharmacokinetics and pharmacology
The pharmacokinetic properties of Sutherlandia have
largely not been assessed[40]. We have demonstrated in
vitro effects of Sutherlandia on CYP3A4, P-gp, and PXR
[35]. Sutherlandia produced near complete inhibition of
CYP3A4 (96%). P-gp activity was moderate under expo-
sure of Sutherlandia, showing 19–31% of the activity
strength relative to verapamil. A PXR assay demonstrated
a greater than 2-fold activation with exposure to Sutherlan-
dia which was dose-dependent (P < 0.01). Once again, in
spite of the relatively high concentrations used in the in
vitro experiments, these results tentatively suggest that
human consumption of Sutherlandia could affect antiret-
roviral drug metabolism leading to bi-directional drugPage 3 of 6
(page number not for citation purposes)
Nutrition Journal 2005, 4:19 http://www.nutritionj.com/content/4/1/19interactions and loss of therapeutic efficacy. In vivo human
studies are required to determine if there is a clinically rel-
evant drug/herb interaction and if so what the true extent
of the interaction is.
Toxicity
Sutherlandia has a relatively long history of seemingly safe
usage in Africa. Known side effects include occasional
mild diarrhea, dry mouth, mild diuresis, and dizzyness in
cachectic patients [38,39]. An extensive toxicology screen-
ing in a primate model using dosages up to 9 times greater
than the recommended dose of 9 mg/kg/day did not iden-
tify clinical, hematological or physiologic toxicity with
Sutherlandia [45].
L-canavanine may be associated with important toxicities
including a systemic lupus erythematous syndrome [46].
The non-protein amino acid can be incorporated into pro-
tein in place of arginine and may, after long term usage,
result in autoimmunity [47,48]. Rare reports of tera-
togenicity and induction of abortion exist [49].
Discussion
The widespread use of herbal compounds by Africans liv-
ing with HIV/AIDS should be of concern to clinicians and
policy makers. Clearly, patients will continue to access tra-
ditional healing systems as it is important to local cultural
values and beliefs. Therefore, efforts should be made by
mainstream health professionals to provide validated
information to traditional healers and patients on the
judicious use of herbal remedies. This may reduce harm
through failed expectations, pharmacologic adverse
events and unnecessary added therapeutic costs. Efforts
should also be directed at evaluating the possible benefits
of natural products in HIV treatment.
It is not unreasonable to suggest that some products may
have therapeutic benefits as examples from history and
the recent past have provided us with effective anti-malar-
ials [50] and cancer treatments[51]. Indeed, some of the
earliest forms of protease inhibitors were derived from
natural products [52-54]. Efforts should be directed at
determining the therapeutic efficacy of these remedies as
well as the possibility of interactions through systematic
research and clinical trials.
Several studies have highlighted key problems related to
primary care delivery by traditional healers in Africa
[8,55,56]. Key issues include hygiene, toxicity and finan-
cial cost. Traditional healers have been implicated in the
spread of blood borne diseases including HIV and other
infectious disease by the re-use of medical instruments
and lack of hand washing [8,55,56]. Prescriptions to take
toxic plants for HIV treatment have also resulted in severe
adverse events, including death[56]. Recent policy efforts
have recognized the substantial use of traditional medi-
cines and several African nations have included tradi-
tional healers in educational campaigns in order to
instruct them on safe and hygienic practices, condom dis-
tribution and knowledge dissemination[2,5,6,14,57].
Despite the relatively high concentrations of herbals used
in our in vitro work, the results serve as a warning and sug-
gest that biologically active constituents of these herbal
remedies clearly may have an effect on HIV drug metabo-
lism as a result of their inhibitory activity on enzymes and
efflux drug transporter systems. These results highlight the
need for in vivo investigations and circumspection when
utilizing herbal drugs as routine care for HIV patients and
underscores the need for clinical studies in humans to
unveil any possible drug interaction of these herbal agents
with antiretrovirals. Failure to do this may result in bi-
directional drug interactions that may put patients at risk
for treatment failure, viral resistance or drug toxicity.
Cultural values are an inherent part of healthcare and an
important component of practicing evidence-based
healthcare [58]. In the context of HIV treatment in Africa,
patients often choose traditional healing systems as pri-
mary care. This, coupled with the difficulties in accessing
antiretroviral treatment, justify further efforts to deter-
mine the scope of traditional medicine use, identify the
negative consequences of this practice and evaluate the
benefits of herbal remedies. In addition, it is important to
understand the values of those providing mainstream
healthcare and those practicing traditional medicine as
their perspectives provide highly relevant social inferences
and should be interpreted with an attempt to understand
their cultural worldviews and practices.
In conclusion, given the Global Fund's recent announce-
ment of funds to make anti-retroviral therapy widely
available in Africa, and the South African Ministry of
Health, along with member states and NGO's endorse-
ment of the use of traditional African herbs such as
Hypoxis and Sutherlandia as HIV/AIDS remedies [17], ini-
tiating policy on herbal medicines should be based on
research evidence. Efforts are required to determine the
safety, efficacy and pharmacological profile of the many
herbal compounds used in Africa. Collaboration with tra-
ditional healers is justified to fully understand what rem-
edies are in use for HIV and to educate those providing
alternative medical services against unsafe practices.
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